ImmuCell (ICCC) vs Anbio Biotechnology (NNNN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
ImmuCell (ICCC) has outperformed Anbio Biotechnology (NNNN) over the past year, gaining 50.2% versus a loss of 83.4%. Anbio Biotechnology is the larger company by market cap ($201.5 million vs $87.6 million), about 2.3 times the size. On valuation, Anbio Biotechnology trades at a lower trailing P/E (30.6x vs 137.9x for ImmuCell).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ICCC | NNNN |
|---|---|---|
| Share price | $9.65 | $4.59 |
| Market cap | $87.64M | $201.46M |
| 1-day change | -0.41% | -6.33% |
| YTD return | +57.56% | -83.70% |
| 1-year return | +50.23% | -83.37% |
| 5-year return | +4.42% | — |
| P/E ratio (TTM) | 137.86 | 30.60 |
| EPS (TTM) | $0.07 | $0.15 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $12.10 | $44.73 |
| 52-week low | $4.52 | $4.56 |
| Distance from 52-week high | -20.25% | -89.74% |
| Average volume | 22.88K | 147.21K |
| Shares outstanding | 9.08M | 43.89M |
| Employees | — | 27 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Anbio Biotechnology is about 2.3 times larger than ImmuCell by market value ($201.46M vs $87.64M).
- ICCC has outperformed NNNN by 133.6 percentage points over the past year.
- ImmuCell trades at a higher earnings multiple (137.9x vs 30.6x trailing P/E).
About Anbio Biotechnology
NNNN stock →Anbio Biotechnology provides in vitro diagnostics (IVD) products in the European Union, the Asia Pacific, North America, South America, and internationally. The company offers lateral flow immunoassay, fluorescence immunoassay, loop-mediated isothermal amplification, SHA dry chemistry, chemiluminescence immunoassay, and real-time polymerase chain reaction solutions; and SARS-CoV-2 and SARS-CoV-2/Flu A/Flu B antigen rapid test kits.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 27 employees
ICCC vs NNNN FAQ
Which is bigger, ImmuCell or Anbio Biotechnology?
Anbio Biotechnology (NNNN) is larger, with a market capitalization of $201.46M compared with $87.64M for ImmuCell (ICCC).
Which stock has performed better over the past year, ICCC or NNNN?
ICCC returned +50.23% over the past 12 months, compared with -83.37% for NNNN (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, ICCC or NNNN?
NNNN has the lower trailing P/E at 30.6, versus 137.9 for ICCC. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are ImmuCell and Anbio Biotechnology in the same industry?
Yes. Both are classified in the Biotechnology: In Vitro & In Vivo Diagnostic Substances industry within the Health Care sector.